ESC Congress 2026 delivers the first dedicated ESC guideline on cardiovascular disease in chronic kidney disease, presented Saturday 29 August. It formalises care for a huge overlap population long excluded from trials, arriving exactly as SGLT2 inhibitors, finerenone and GLP-1 agonists have turned cardio-renal protection into a treatable continuum.
